Biomarkers in sepsis

Current Infectious Disease Reports

Volumn 15, Issue 5, 2013, Pages 413-420

  Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarkers; Sepsis

Indexed keywords

ADENOSINE; ANTIBIOTIC AGENT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CD64 ANTIGEN; D DIMER; DNA; DOBUTAMINE; DROTRECOGIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID BINDING PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTATHIONE; INOSITOL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; LACTIC ACID; MESSENGER RNA; METALLOPROTEINASE; MICRORNA; PHOSPHATIDYLSERINE; PLASMA PROTEIN; PROCALCITONIN; SPHINGOMYELIN; STROMELYSIN; STROMELYSIN 2; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR;

ACUTE LUNG INJURY; AGE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APACHE; APOPTOSIS; AREA UNDER THE CURVE; BACTERIAL INFECTION; CHEMILUMINESCENCE IMMUNOASSAY; COMORBIDITY; CONCENTRATION (PARAMETERS); DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DNA MODIFICATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LEUKOCYTE; METABOLIC REGULATION; METABOLITE; METABOLOMICS; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOSOME; PATHOGENESIS; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION;

EID: 84884589233     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0357-x     Document Type: Review

References (69)

1. Marshall JC. Biomarkers of sepsis. Curr Infect Dis Rep. 2006;8:351-7.
2. Moyer MW. New biomarkers sought for improving sepsis management and care. Nat Med. 2012;18:999.
3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580-637.
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10.
5. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-96.
6. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis. 2012;73:221-7.
7. Pickering JW, Endre ZH. New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol. 2012;7:1355-64.
8. Tzoulaki I, Liberopoulos G, Ioannidis JP. Use of reclassification for assessment of improved prediction: an empirical evaluation. Int J Epidemiol. 2011;40:1094-105.
9. Irwin RJ, Irwin TC. A principled approach to setting optimal diagnostic thresholds: where ROC and indifference curves meet. Eur J Intern Med. 2011;22:230-4.
10. Lee M, Kong L, Weissfeld L. Multiple imputation for left-censored biomarker data based on Gibbs sampling method. Stat Med. 2012;31:1838-48.
11. Richards G, Levy H, Laterre PF, Feldman C, Woodward B, Bates BM, et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intensive Care Med. 2011;26:34-40.
12. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
13. Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J, Casner E, et al. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock. 2009;32:35-9.
14. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;303:739-46.
15. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77.
16. Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med. 2011;184:514-20.
17. Azevedo JR, Torres OJ, Czeczko NG, Tuon FF, Nassif PA, Souza GD. Procalcitonin as a prognostic biomarker of severe sepsis and septic shock. Rev Col Bras Cir. 2012;39:456-61.
18. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55:651-62.
19. Koch A, Tacke F. Why high suPAR is not super - diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU. Crit Care. 2011;15:1020.
20. de Pablo R, Monserrat J, Reyes E, Diaz D, Rodriguez-Zapata M, de la Hera A, et al. Circulating sICAM-1 and sE-Selectin as biomarker of infection and prognosis in patients with systemic inflammatory response syndrome. Eur J Intern Med. 2013;24:132-8.
21. Rodelo JR, De la Rosa G, Valencia ML, Ospina S, Arango CM, Gomez CI, et al. D-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med. 2012;30:1991-9.
22. Wong HR, Cvijanovich N, Wheeler DS, Bigham MT, Monaco M, Odoms K, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med. 2008;178:276-82.
23. Wong HR. Clinical review: sepsis and septic shock - the potential of gene arrays. Crit Care. 2012;16:204.
24. Lissauer ME, Johnson SB, Bochicchio GV, Feild CJ, Cross AS, Hasday JD, et al. Differential expression of toll-like receptor genes: sepsis compared with sterile inflammation 1 day before sepsis diagnosis. Shock. 2009;31:238-44.
25. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med. 2009;37:882-8.
26. Wong HR, Cvijanovich NZ, Allen GL, Thomas NJ, Freishtat RJ, Anas N, et al. Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med. 2011;39:2511-7.
27. Wang HJ, Zhang PJ, Chen WJ, Feng D, Jia YH, Xie LX. Four serum microRNAs identified as diagnostic biomarkers of sepsis. J Trauma Acute Care Surg. 2012;73:850-4.
28. Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie LX. Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. Clin Chem Lab Med. 2012;50:1423-8.
29. Fitting C, Parlato M, Adib-Conquy M, Memain N, Philippart F, Misset B, et al. DNAemia detection by multiplex PCR and biomarkers for infection in systemic inflammatory response syndrome patients. PLoS One. 2012;7:e38916.
30. Chen Q, Ye L, Jin Y, Zhang N, Lou T, Qiu Z, et al. Circulating nucleosomes as a predictor of sepsis and organ dysfunction in critically ill patients. Int J Infect Dis. 2012;16:e558-64.
31. Martins GA, Kawamura MT, Carvalho Mda G. Detection of DNA in the plasma of septic patients. Ann N Y Acad Sci. 2000;906:134-40.
32. Butt AN, Swaminathan R. Overview of circulating nucleic acids in plasma/serum. Ann N Y Acad Sci. 2008;1137:236-42.
33. Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kajikawa O, et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med. 2008;178:710-20.
34. Thair SA, Walley KR, Nakada TA, McConechy MK, Boyd JH, Wellman H, et al. A single nucleotide polymorphism in NF-κB inducing kinase is associated with mortality in septic shock. J Immunol. 2011;186:2321-8.
35. Wacharasint P, Nakada TA, Boyd JH, Russell JA, Walley KR. AA genotype of IL-8-251A/T is associated with low PaO(2)/FiO(2) in critically ill patients and with increased IL-8 expression. Respirology. 2012;17:1253-60.
36. Nakada TA, Russell JA, Boyd JH, Aguirre-Hernandez R, Thain KR, Thair SA, et al. beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med. 2010;181:143-9.
37. Serkova NJ, Standiford TJ, Stringer KA. The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. Am J Respir Crit Care Med. 2011;184:647-55.
38. Stringer KA, Serkova NJ, Karnovsky A, Guire K, Paine 3rd R, Standiford TJ. Metabolic consequences of sepsis-induced acute lung injury revealed by plasma (1)H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol. 2011;300:L4-L11.
39. Schmerler D, Neugebauer S, Ludewig K, Bremer-Streck S, Brunkhorst FM, Kiehntopf M. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J Lipid Res. 2012;53:1369-75.
40. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15:R63.
41. Savva A, Raftogiannis M, Baziaka F, Routsi C, Antonopoulou A, Koutoukas P, et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect. 2011;63:344-50.
42. Uusitalo-Seppala R, Huttunen R, Tarkka M, Aittoniemi J, Koskinen P, Leino A, et al. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med. 2012;272:247-56.
43. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38:1418-28.
44. Lipinska-Gediga M, Mierzchala M, Durek G. Pro-atrial natriuretic peptide (pro-ANP) level in patients with severe sepsis and septic shock: prognostic and diagnostic significance. Infection. 2012;40:303-9.
45. Jo YH, Kim K, Lee JH, Rhee JE, Lee JH, Kang KW, et al. Heart-type fatty acid-binding protein as a prognostic factor in patients with severe sepsis and septic shock. Am J Emerg Med. 2012;30:1749-55.
46. Zhang ZC, Dai HW, Yu YH, Yang JD, Hu CB. Usefulness of heart-type fatty acid-binding protein in patients with severe sepsis. J Crit Care. 2012;27:415.e13-8.
47. Chung H, Corti A, Crippa L, Schneider F, Metz-Boutigue MH, Garnero P. Development of an immunoassay for the derived-peptide of chromogranin A, vasostatin-I (1-76): assessment of severity in patients with sepsis. Biomarkers. 2012;17:430-4.
48. Vorwerk C, Coats TJ. The prognostic value of tissue oxygen saturation in emergency department patients with severe sepsis or septic shock. Emerg Med J. 2012;29:699-703.
49. Desai S, Jones SL, Turner KL, Hall J, Moore LJ. Nucleated red blood cells are associated with a higher mortality rate in patients with surgical sepsis. Surg Infect. 2012;13:360-5.
50. Merino CA, Martinez FT, Cardemil F, Rodriguez JR. Absolute eosinophils count as a marker of mortality in patients with severe sepsis and septic shock in an intensive care unit. J Crit Care. 2012;27:394-9.
51. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426-35.
52. Vouloumanou EK, Plessa E, Karageorgopoulos DE, Mantadakis E, Falagas ME. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med. 2011;37:747-62.
53. Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012;64:3034-42.
54. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171:1322-31.
55. Derive M, Gibot S. Urine strem-1 assessment in diagnosing sepsis and sepsis-related acute kidney injury. Crit Care. 2011;15:1013.
56. Oku R, Oda S, Nakada TA, Sadahiro T, Nakamura M, Hirayama Y, et al. Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2013;61:112-7.
57. Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, et al. Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis. 2012;12:157.
58. Gamez-Diaz LY, Enriquez LE, Matute JD, Velasquez S, Gomez ID, Toro F, et al. Diagnostic accuracy of HMGB-1, sTREM-1, and CD64 as markers of sepsis in patients recently admitted to the emergency department. Acad Emerg Med. 2011;18:807-15.
59. Gibot S, Bene MC, Noel R, Massin F, Guy J, Cravoisy A, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med. 2012;186:65-71.
60. Gros A, Roussel M, Sauvadet E, Gacouin A, Marque S, Chimot L, et al. The sensitivity of neutrophil CD64 expression as a biomarker of bacterial infection is low in critically ill patients. Intensive Care Med. 2012;38:445-52.
61. Punyadeera C, Schneider EM, Schaffer D, Hsu HY, Joos TO, Kriebel F, et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J Emerg Trauma Shock. 2010;3:26-35.
62. Linder A, Akesson P, Brink M, Studahl M, Bjorck L, Christensson B. Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. Crit Care Med. 2011;39:812-7.
63. Al Shuaibi M, Bahu RR, Chaftari AM, Al Wohoush I, Shomali W, Jiang Y, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis. 2013;56:943-50.
64. Tsalik EL, Jaggers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med. 2012;43:97-106.
65. Tromp M, Lansdorp B, Bleeker-Rovers CP, Gunnewiek JM, Kullberg BJ, Pickkers P. Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement. J Infect. 2012;65:292-301.
66. Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011;105:1939-45.
67. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med. 2011;39:1792-9.
68. Annane D, Mira JP, Ware LB, Gordon AC, Sevransky J, Stuber F, et al. Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated). Ann Intensive Care. 2012;2:15.
69. Lehmann C, Sharawy N, Zhou J, Pavlovic D. Metabolomic analysis as biomarker to study steroid hormone administration in sepsis. Med Hypotheses. 2012;79:329-30.